期刊
LANCET
卷 385, 期 9979, 页码 1778-1788出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(15)60647-X
关键词
-
资金
- American Board of Internal Medicine
- Almirall
- APT Pharma
- American Thoracic Society
- AstraZeneca
- Baxter
- Boerhinger Ingelheim
- Chiesi
- Cipla
- Cleveland Clinic
- COPD Foundation
- CSA
- CSL
- California Thoracic Society
- Daiichi Sankyo
- Elevation Pharma
- Forest
- GSK
- Gilead
- Johnson Johnson
- MedImmune
- Novartis
- Pearl
- Pfizer
- Pulmatrix
- Regeneron
- Takeda
- Theron
- National Heart, Lung and Blood Institute
- Nebraska Department of Health and Human Services
- National Institutes of Health
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide. COPD, however, is a heterogeneous collection of diseases with differing causes, pathogenic mechanisms, and physiological effects. Therefore a comprehensive approach to COPD prevention will need to address the complexity of COPD. Advances in the understanding of the natural history of COPD and the development of strategies to assess COPD in its early stages make prevention a reasonable, if ambitious, goal.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据